← All trials
NCT01689363
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2012
- Primary completion
- Nov 1, 2012
- Completion date
- Dec 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 253
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Amphastar PharmaceuticalsLead sponsor
- Amphastar PharmaceuticalsStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.